The present invention relates to the use of a nonimmunosuppressive
cyclosporin A derivative for reducing mitochondrial dysfunction and the
rate of apoptosis of muscle cells of patients diagnosed with Ullrich
congenital muscular dystrophy or Bethlem myopathy.